×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
OPK – opko health, inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
OPK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/7
01:30 pm
opk
OPKO Health, Inc. (NASDAQ: OPK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Neutral
Report
OPKO Health, Inc. (NASDAQ: OPK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
4/4
08:00 am
opk
OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program
Medium
Report
OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program
4/3
08:48 am
opk
GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication [Yahoo! Finance]
Low
Report
GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication [Yahoo! Finance]
3/19
08:04 am
opk
OPKO Health, Inc. (NASDAQ: OPK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Medium
Report
OPKO Health, Inc. (NASDAQ: OPK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
3/17
08:00 am
opk
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
Medium
Report
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
3/14
10:50 am
opk
GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis [Yahoo! Finance]
Low
Report
GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis [Yahoo! Finance]
3/13
08:43 am
opk
GeneDx to Showcase Key Research and Innovation at the 2025 American College of Medical Genetics (ACMG) Annual Meeting [Yahoo! Finance]
Low
Report
GeneDx to Showcase Key Research and Innovation at the 2025 American College of Medical Genetics (ACMG) Annual Meeting [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/3
05:23 pm
opk
Form SCHEDULE 13D/A OPKO HEALTH, INC. Filed by: FROST PHILLIP MD ET AL
Medium
Report
Form SCHEDULE 13D/A OPKO HEALTH, INC. Filed by: FROST PHILLIP MD ET AL
4/3
05:21 pm
opk
Form SCHEDULE 13D/A OPKO HEALTH, INC. Filed by: HSIAO JANE PH D
Medium
Report
Form SCHEDULE 13D/A OPKO HEALTH, INC. Filed by: HSIAO JANE PH D
4/1
05:22 pm
opk
Form 4 OPKO HEALTH, INC. For: Apr 01 Filed by: FROST PHILLIP MD ET AL
Low
Report
Form 4 OPKO HEALTH, INC. For: Apr 01 Filed by: FROST PHILLIP MD ET AL
4/1
05:14 pm
opk
Form 8-K OPKO HEALTH, INC. For: Mar 28
Low
Report
Form 8-K OPKO HEALTH, INC. For: Mar 28
3/28
05:22 pm
opk
Form 4 OPKO HEALTH, INC. For: Mar 28 Filed by: FROST PHILLIP MD ET AL
Medium
Report
Form 4 OPKO HEALTH, INC. For: Mar 28 Filed by: FROST PHILLIP MD ET AL
3/28
07:29 am
opk
Form 8-K OPKO HEALTH, INC. For: Mar 27
Low
Report
Form 8-K OPKO HEALTH, INC. For: Mar 27
3/21
05:20 pm
opk
Form 10-K/A OPKO HEALTH, INC. For: Dec 31
Neutral
Report
Form 10-K/A OPKO HEALTH, INC. For: Dec 31
3/17
05:28 pm
opk
Form 4 OPKO HEALTH, INC. For: Mar 17 Filed by: FROST PHILLIP MD ET AL
Low
Report
Form 4 OPKO HEALTH, INC. For: Mar 17 Filed by: FROST PHILLIP MD ET AL
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/5
OPKO Health's BioReference Laboratories to Introduce Coronavirus Disease (COVID-19) Test
29.2%
4/20 Form 4 Opko Health, Inc. For: Apr 17 Filed by: FROST PHILLIP MD ET AL 16.5%
3/17 OPKO Health's BioReference Laboratories and NYC Health + Hospitals Enter into Laboratory Collaboration to Provide Testing for Coronavirus Disease 2019 (COVID-19) 13.1%
3/4 Form 4 Opko Health, Inc. For: Mar 03 Filed by: Frost Gamma Investments Trust 12.2%
3/13 Form 4 Opko Health, Inc. For: Mar 12 Filed by: Japour Anthony J 11.8%
4/6 Form 4 Opko Health, Inc. For: Apr 03 Filed by: FROST PHILLIP MD ET AL 11.6%
6/28 Novitas Issues Proposed Local Coverage Determination for the 4Kscore® Test 9.9%
4/8 Form 4 Opko Health, Inc. For: Apr 07 Filed by: Frost Gamma Investments Trust 7.8%
9/23 Form 8-K Opko Health, Inc. For: Sep 21 6.5%
3/10 Opko Health Inc. (NASDAQ: OPK) had its price target raised by analysts at Piper Sandler from to . 6.2%
4/20 Form 4 Opko Health, Inc. For: Apr 17 Filed by: FROST PHILLIP MD ET AL 16.5%
3/17 OPKO Health's BioReference Laboratories and NYC Health + Hospitals Enter into Laboratory Collaboration to Provide Testing for Coronavirus Disease 2019 (COVID-19) 13.1%
3/4 Form 4 Opko Health, Inc. For: Mar 03 Filed by: Frost Gamma Investments Trust 12.2%
3/13 Form 4 Opko Health, Inc. For: Mar 12 Filed by: Japour Anthony J 11.8%
4/6 Form 4 Opko Health, Inc. For: Apr 03 Filed by: FROST PHILLIP MD ET AL 11.6%
6/28 Novitas Issues Proposed Local Coverage Determination for the 4Kscore® Test 9.9%
4/8 Form 4 Opko Health, Inc. For: Apr 07 Filed by: Frost Gamma Investments Trust 7.8%
9/23 Form 8-K Opko Health, Inc. For: Sep 21 6.5%
3/10 Opko Health Inc. (NASDAQ: OPK) had its price target raised by analysts at Piper Sandler from to . 6.2%
TOP News Decliners
3/9
Edited Transcript of OPK earnings conference call or presentation 26-Feb-20 9:30pm GMT [Yahoo! Finance News]
-26.0%
5/7 Q1/2019 3/31/2019 EPS -0.140 ZacksConsensus -0.060 ActVsEst (0.080) - Miss -14.3%
10/24 OPKO Health, Inc. Announces Pricing of its Offering of Common Stock -14.3%
10/24 Form 424B5 Opko Health, Inc. -14.2%
3/13 Coronavirus activity roundup - healthcare [Seeking Alpha] -11.6%
3/7 Opko Health Inc. (NASDAQ: OPK) had its "buy" rating re-affirmed by analysts at Piper Sandler. -10.5%
3/20 Form 4 Opko Health, Inc. For: Mar 19 Filed by: Frost Gamma Investments Trust -8.5%
10/21 OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency -7.8%
11/5 OPKO Health Reports 2019 Third Quarter Business Highlights and Financial Results -7.5%
5/13 Form 4 Opko Health, Inc. For: May 10 Filed by: FROST PHILLIP MD ET AL -6.7%
5/7 Q1/2019 3/31/2019 EPS -0.140 ZacksConsensus -0.060 ActVsEst (0.080) - Miss -14.3%
10/24 OPKO Health, Inc. Announces Pricing of its Offering of Common Stock -14.3%
10/24 Form 424B5 Opko Health, Inc. -14.2%
3/13 Coronavirus activity roundup - healthcare [Seeking Alpha] -11.6%
3/7 Opko Health Inc. (NASDAQ: OPK) had its "buy" rating re-affirmed by analysts at Piper Sandler. -10.5%
3/20 Form 4 Opko Health, Inc. For: Mar 19 Filed by: Frost Gamma Investments Trust -8.5%
10/21 OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency -7.8%
11/5 OPKO Health Reports 2019 Third Quarter Business Highlights and Financial Results -7.5%
5/13 Form 4 Opko Health, Inc. For: May 10 Filed by: FROST PHILLIP MD ET AL -6.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: